Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
Cancer Discovery2022Vol. 13(1), pp. 114–131
Citations Over TimeTop 1% of 2022 papers
Nicholas A. Vitanza, Ashley Wilson, Wenjun Huang, Kristy Seidel, Christopher Brown, Joshua A. Gustafson, Jason K. Yokoyama, Adam Johnson, Blake A. Baxter, Ryan W. Koning, Aquene N. Reid, Michael Meechan, Matthew C. Biery, Carrie Myers, Stephanie Rawlings-Rhea, Catherine M. Albert, Samuel R. Browd, Jason S. Hauptman, Amy Lee, Jeffrey G. Ojemann, Michael E. Berens, Matthew D. Dun, Jessica Foster, Erin Crotty, Sarah Leary, Bonnie Cole, Francisco A. Perez, Jason N. Wright, Rimas J. Orentas, Tony Chour, Evan W. Newell, Jeffrey R. Whiteaker, Lei Zhao, Amanda G. Paulovich, Navin Pinto, Juliane Gust, Rebecca Gardner, Michael C. Jensen, Julie R. Park
Abstract
This is the first report of repeatedly dosed intracranial B7-H3 CAR T cells for patients with DIPG and includes preliminary tolerability, the detection of CAR T cells in the CSF, CSF cytokine elevations supporting locoregional immune activation, and the feasibility of serial mass spectrometry from both serum and CSF. This article is highlighted in the In This Issue feature, p. 1.
Related Papers
- → LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis(2021)19 cited
- → MiRNA-93 functions as an oncogene in glioma by directly targeting RBL2.(2018)25 cited
- → Melanoma-associated antigen A2 is overexpressed in glioma and associated with poor prognosis in glioma patients(2018)7 cited
- → A dynamical model of combination therapy applied to glioma(2022)2 cited
- → CPLX2 is a novel tumor suppressor and improves the prognosis in glioma(2023)